Immediate Impact
2 from Science/Nature 63 standout
Citing Papers
The hallmarks of cancer immune evasion
2024 Standout
Targeting ROS in cancer: rationale and strategies
2024 Standout
Works of Rishu Agarwal being referenced
Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma
2018 Standout
COMBINATION IBRUTINIB (IBR) AND VENETOCLAX (VEN) FOR THE TREATMENT OF MANTLE CELL LYMPHOMA (MCL): PRIMARY ENDPOINT ASSESSMENT OF THE PHASE 2 AIM STUDY
2017
Author Peers
| Author | Last Decade | Papers | Cites | |||
|---|---|---|---|---|---|---|
| Rishu Agarwal | 253 | 299 | 228 | 17 | 422 | |
| Nilima Parry‐Jones | 308 | 309 | 166 | 19 | 485 | |
| Iwona Wlodarska | 227 | 245 | 136 | 14 | 427 | |
| Evgenii A. Osmanov | 202 | 347 | 311 | 22 | 484 | |
| Guido Parvis | 143 | 233 | 193 | 24 | 426 | |
| GJ van Ommen | 155 | 254 | 156 | 13 | 492 | |
| Manfred Welslau | 223 | 325 | 295 | 26 | 483 | |
| Nele Fourneau | 143 | 214 | 180 | 14 | 380 | |
| Dominique Penther | 249 | 234 | 116 | 32 | 429 | |
| Huiqiang Huang | 143 | 290 | 263 | 20 | 446 | |
| Maria Grazia Roberti | 294 | 248 | 142 | 21 | 460 |
All Works
Login with ORCID to disown or claim papers
Loading papers...